Ipamorelin

Ipamorelin is a selective growth hormone secretagogue developed by Novo Nordisk. It stimulates GH release without significantly affecting cortisol or prolactin levels. Has been studied in clinical trials for postoperative recovery.

Mechanism of Action

Summary: Selectively activates ghrelin receptors to stimulate growth hormone release without significantly affecting cortisol or prolactin levels. Mechanisms (reported/proposed across domains): Growth hormone axis • Selectively binds and activates ghrelin receptor (GHS-R1a) in the pituitary, triggering GH release with high selectivity. • Produces dose-proportional increase in circulating GH...

Safety Profile

Investigational - Development Discontinued

Research Dosing

Dose: 100–300 mcg · Route: Subcutaneous (SC) · Frequency: 1–3× daily · Duration: 8–12 weeks

Categories

  • Research Only
  • Growth Hormone
  • IGF-1 Elevation
  • Body Composition
  • Anti-Aging
  • Muscle Support
  • Fat Metabolism
  • Sleep Quality
  • Clinical Data Available
  • Not FDA Approved

Related Peptides

The Leading Community for Trusted Peptide Research & Insights

Join a vibrant community sharing real peptide experiences, clinical research, and proven protocols. Data-backed, open, and censorship-free.